


## Terconazole-d<sub>4</sub>

<b>Cat. No.:</b>	HY-B1790S		
<b>CAS No.:</b>	1398065-50-3		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>27</sub> D <sub>4</sub> Cl <sub>2</sub> N <sub>5</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	536.49		
<b>Target:</b>	Fungal		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Terconazole-d <sub>4</sub> is the deuterium labeled Terconazole. Terconazole is a broad-spectrum antifungal medication for the treatment of vaginal yeast infection.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Tolman EL, et al. Anticandidal activities of terconazole, a broad-spectrum antimycotic. *Antimicrob Agents Chemother.* 1986 Jun;29(6):986-91.
- [3]. Van Cutsem J, et al. The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. *Am J Obstet Gynecol.* 1991 Oct;165(4 Pt 2):1200-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA